Free Trial

Adverum Biotechnologies (ADVM) Competitors

Adverum Biotechnologies logo
$2.77 -0.07 (-2.46%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 0.00 (-0.18%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADVM vs. DSGN, UPXI, MDWD, BTMD, LRMR, CGC, CRGX, ACIU, NMRA, and FDMT

Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Design Therapeutics (DSGN), Upexi (UPXI), MediWound (MDWD), biote (BTMD), Larimar Therapeutics (LRMR), Canopy Growth (CGC), CARGO Therapeutics (CRGX), AC Immune (ACIU), Neumora Therapeutics (NMRA), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

Adverum Biotechnologies vs. Its Competitors

Adverum Biotechnologies (NASDAQ:ADVM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

In the previous week, Adverum Biotechnologies and Adverum Biotechnologies both had 1 articles in the media. Adverum Biotechnologies' average media sentiment score of 0.94 beat Design Therapeutics' score of 0.93 indicating that Adverum Biotechnologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adverum Biotechnologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Design Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Adverum Biotechnologies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Design Therapeutics' return on equity of -22.85% beat Adverum Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adverum BiotechnologiesN/A -130.53% -66.31%
Design Therapeutics N/A -22.85%-22.02%

Design Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Design Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$1M57.87-$130.93M-$6.40-0.43
Design TherapeuticsN/AN/A-$49.59M-$0.99-4.02

48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by insiders. Comparatively, 31.2% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adverum Biotechnologies presently has a consensus price target of $23.80, suggesting a potential upside of 759.21%. Design Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 0.50%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Adverum Biotechnologies is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Design Therapeutics beats Adverum Biotechnologies on 7 of the 12 factors compared between the two stocks.

Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADVM vs. The Competition

MetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$59.33M$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E RatioN/A19.8828.0419.84
Price / Sales57.87305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book0.817.678.125.65
Net Income-$130.93M-$55.28M$3.25B$258.00M
7 Day Performance9.06%2.50%0.97%2.09%
1 Month Performance20.96%11.70%7.36%11.13%
1 Year Performance-70.78%4.89%31.31%18.40%

Adverum Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADVM
Adverum Biotechnologies
4.4165 of 5 stars
$2.77
-2.5%
$23.80
+759.2%
-67.7%$59.33M$1M-0.43190
DSGN
Design Therapeutics
0.4659 of 5 stars
$4.00
+2.0%
$4.00
-9.9%$227.08MN/A-4.0440News Coverage
UPXI
Upexi
1.7585 of 5 stars
$5.96
+10.6%
$16.00
+168.5%
-13.8%$225.97M$16.56M0.00130News Coverage
Gap Up
High Trading Volume
MDWD
MediWound
1.6367 of 5 stars
$20.47
+2.2%
$31.80
+55.3%
-1.4%$221.24M$19.21M-9.7980Positive News
BTMD
biote
3.3269 of 5 stars
$4.04
-1.0%
$8.00
+98.0%
-49.5%$221.03M$199.38M6.62194
LRMR
Larimar Therapeutics
2.2663 of 5 stars
$3.45
+2.1%
$18.50
+436.2%
-67.1%$220.90MN/A-2.3230Positive News
CGC
Canopy Growth
0.4488 of 5 stars
$1.17
+3.5%
N/A-85.1%$215.13M$225.65M-0.293,150Positive News
CRGX
CARGO Therapeutics
2.3335 of 5 stars
$4.59
flat
$15.40
+235.5%
-74.0%$211.65MN/A-0.99116High Trading Volume
ACIU
AC Immune
2.1805 of 5 stars
$2.08
+2.0%
$12.00
+476.9%
-42.5%$208.85M$31.02M-3.59140Positive News
NMRA
Neumora Therapeutics
2.3949 of 5 stars
$1.27
-1.6%
$7.50
+490.6%
-85.6%$205.42MN/A-0.79108Positive News
Analyst Forecast
Gap Up
FDMT
4D Molecular Therapeutics
2.2164 of 5 stars
$4.38
+2.3%
$29.56
+574.8%
-76.0%$202.93M$40K-1.38120

Related Companies and Tools


This page (NASDAQ:ADVM) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners